Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell–stimulatory capacity

详细信息    查看全文

• 作者：Corbin Clawson ; Chien-Tze Huang ; Diahnn Futalan ; Daniel Martin Seible ; Rebecca Saenz ; Marie Larsson ; Wenxue Ma ; Boris Minev ; Fiona Zhang ; Mihri Ozkan ; Cengiz Ozkan ; Sadik Esener ; Davorka Messmer
• 关键词：PLGA nanoparticles ; Peptide conjugation ; Immune stimulation ; Dendritic cells ; HMGB1
• 刊名：Nanomedicine: Nanotechnology, Biology and Medicine
• 出版年：2010
• 出版时间：October 2010
• 年：2010
• 卷：6
• 期：5
• 页码：651-661
• 全文大小：941 K

文摘

Nanoparticles (NPs) are attractive carriers for vaccines. We have previously shown that a short peptide (Hp91) activates dendritic cells (DCs), which are critical for initiation of immune responses. In an effort to develop Hp91 as a vaccine adjuvant with NP carriers, we evaluated its activity when encapsulated in or conjugated to the surface of poly(d,l-lactic-co-glycolic) acid (PLGA) NPs. We found that Hp91, when encapsulated in or conjugated to the surface of PLGA-NPs, not only activates both human and mouse DCs, but is in fact more potent than free Hp91. Hp91 packaged within NPs was about fivefold more potent than the free peptide, and Hp91 conjugated to the surface of NPs was 20-fold more potent than free Hp91. Because of their capacity to activate DCs, such NP-Hp91 systems are promising as delivery vehicles for subunit vaccines against infectious disease or cancer.

From the Clinical Editor

In this paper, nanoparticle-based dendritic cell activating vaccines are described and discussed. The authors report that the presented PLGA NP based vaccine constructs increase the potency of the studied vaccine by up to 20-fold, making them promising as delivery vehicles for subunit vaccines against infectious diseases or cancer.